Clinical trials: Lymphoma, T Cell, Peripheral
Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers.
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06870487
- Testing
- PF-08046032, Sasanlimab
- Where
- 4 sites in United States, Spain
- Volunteers
- 6 people
- Sponsor
- Pfizer
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
- Trial name
- NCT04703192
- Testing
- Valemetostat Tosylate
- Where
- 60 sites in United States, Australia and 10 more
- Volunteers
- 155 people
- Sponsor
- Daiichi Sankyo
Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
Phase 1b Safety and Efficacy Study of TRU-016
The purpose of this study is to evaluate the efficacy and safety of TRU-016 in combination with rituximab, in combination with obinutuzumab, in combination with rituximab and idelalisib, or in combination with ibrutinib in…
- Trial name
- NCT01644253
- Testing
- 20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab
- Where
- 8 sites in United States
- Volunteers
- 87 people
- Sponsor
- Aptevo Therapeutics
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Hodgkin's Lymphoma
- Trial name
- NCT01767766
- Testing
- TGR-1202
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- TG Therapeutics, Inc.
Cancer, Pancreatic Cancer
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in…
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
- Trial name
- NCT03678883
- Testing
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 350 people
- Sponsor
- Actuate Therapeutics Inc.
Peripheral T Cell Lymphoma, Progression, Disease
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
This study is to evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria…
- Trial name
- NCT03150602
- Testing
- Pralatrexate
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- Taiwan Mundipharma Pharmaceuticals Ltd.
Peripheral T Cells Lymphoma (PTCL)
Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
This is a 2-part study consisting of a Part 1, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), or Recommended Part 2 Dose (RP2D) of LIS1 as a single agent; followed by a Part 2, to…
- Trial name
- PALT1 (NCT06495723)
- Testing
- LIS1
- Where
- 8 sites in France, Italy
- Volunteers
- 54 people
- Sponsor
- Xenothera SAS
Peripheral T Cell Lymphoma
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
This is a randomized, open-label, active controlled, multi-center, phase 3 clinical study to compare the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with Chidamide in patients with relapsed/refractory…
- Trial name
- NCT04668690
- Testing
- Mitoxantrone Hydrochloride Liposome Injection, Chidamide
- Where
- China
- Volunteers
- 193 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of GNTbm-38 in adult patients with advanced solid tumors and R/R PTCL.
- Trial name
- NCT07842445
- Testing
- GNTbm-38
- Volunteers
- 70 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
PTCL, NK T-Cell Lymphoma
TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
This is a randomized, open-label, multicenter Phase III study evaluating the efficacy and safety of TR115, an EZH2 inhibitor, versus investigator's choice (chidamide, golidocitinib, mitoxantrone liposome, or gemcitabine) in…
- Trial name
- NCT07639879
- Testing
- TR115, Investigator's Choice
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Tarapeutics Science Inc.
Adult T-Cell Leukemia/Lymphoma (ATLL)
A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
This study aims to evaluate the tolerability of OJP-001, a therapeutic system combining photodynamic therapy (PDT) using OMD-001 and extracorporeal circulation therapy using OJE-001 and OJC-001, in patients with adult T-cell…
- Trial name
- NCT07075328
- Testing
- Drug:5-ALA, Device:Photodynamic system
- Where
- 5 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Otsuka Medical Devices Co., Ltd. Japan
Lymphoma, B Cell Lymphoma
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
The is a prospective, open-label, dose-climbing multicenter clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
- Conditions
- Lymphoma, B Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma
- Trial name
- CAR-T，MTD (NCT07048353)
- Testing
- chimeric antigen receptor gene modified T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Hodgkin Disease, Lymphoma, T-Cell, Peripheral
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma.
- Conditions
- Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
- Trial name
- NCT06254495
- Testing
- PF-08046044/SGN-35C
- Where
- 33 sites in United States, Denmark and 4 more
- Volunteers
- 58 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Relapsed or Refractory Non-Hodgkin's Lymphoma
Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
This is an open-label, multicenter, phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in adult subjects with Relapsed/Refractory Non-Hodgkin Lymphomas.
- Trial name
- NCT05965505
- Testing
- AXT-1003
- Where
- 4 sites in China
- Volunteers
- 1 people
- Sponsor
- Axter Therapeutics (Beijing) Co., Ltd
Peripheral T-Cell Lymphoma
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
The primary objective of this study is to determine the overall response rate of KW-0761 for the treatment of patients with relapsed or refractory PTCL. KW-0761 targets CCR4.
- Trial name
- NCT01611142
- Testing
- KW-0761 (mogamulizumab)
- Where
- 15 sites in Denmark, France and 4 more
- Volunteers
- 38 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Peripheral T-Cell Lymphoma
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This study is a phase 2 multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of SP-02L monotherapy in relapsed or refractory patients with peripheral T-cell lymphoma.
- Trial name
- NCT02653976
- Testing
- SP-02L (darinaparsin for injection)
- Where
- 24 sites in Hong Kong, Japan and 2 more
- Volunteers
- 67 people
- Sponsor
- Solasia Pharma K.K.
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or…
- Trial name
- NCT01482962
- Testing
- Alisertib, Pralatrexate, Gemcitabine
- Where
- 151 sites in United States, Australia and 29 more
- Volunteers
- 271 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Relapsed/Refractory Peripheral T Cell Lymphoma
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
This is an open-label, multi-center clinical study to evaluate the efficacy and safety of XNW5004 tablets in subjects with R/R PTCL. The study plans to enroll approximately 50 subjects.
- Trial name
- NCT06702605
- Testing
- XNW5004 tablets
- Volunteers
- 50 people
- Sponsor
- Evopoint Biosciences Inc.
Peripheral T Cell Lymphoma
AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
This is a phase II, open label, multicenter study of AZD4205 administered orally in participants with r/r PTCL to determine its safety, tolerability, PK, and anti-tumor activity.
- Trial name
- NCT06511895
- Testing
- AZD4205
- Where
- 19 sites in China
- Volunteers
- 57 people
- Sponsor
- Dizal Pharmaceuticals
Peripheral T-cell Lymphoma
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
The purpose of this study is to evaluate the activity of romidepsin in patients with progressive or relapsed peripheral T-cell lymphoma (PTCL) who have already been treated with systemic therapy.
- Trial name
- NCT00426764
- Testing
- Romidepsin
- Where
- 90 sites in United States, Australia and 8 more
- Volunteers
- 131 people
- Sponsor
- Celgene